These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1075 related items for PubMed ID: 9198890

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Optimal medical management of peripheral arterial disease.
    Rice TW, Lumsden AB.
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [Abstract] [Full Text] [Related]

  • 6. Endothelial dysfunction in human disease.
    Drexler H, Hornig B.
    J Mol Cell Cardiol; 1999 Jan; 31(1):51-60. PubMed ID: 10072715
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM.
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P.
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [Abstract] [Full Text] [Related]

  • 12. Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells.
    Thum T, Fraccarollo D, Galuppo P, Tsikas D, Frantz S, Ertl G, Bauersachs J.
    Cardiovasc Res; 2006 Apr 01; 70(1):50-60. PubMed ID: 16480696
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effects of ACE inhibition on progression of atherosclerosis.
    Sharpe N.
    J Cardiovasc Pharmacol; 1993 Apr 01; 22 Suppl 9():S9-12. PubMed ID: 7514240
    [Abstract] [Full Text] [Related]

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 01; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 16. [The significance of converting enzyme inhibitor angiotensin I to angiotensin II in treatment of patients with coronary disease].
    Halawa B.
    Pol Merkur Lekarski; 1998 Jan 01; 4(19):32-4. PubMed ID: 9553407
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W, Gmiński J.
    Przegl Lek; 2000 Jan 01; 57(5):291-5. PubMed ID: 11057120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.